SINO BIOPHARM (01177.HK): Subsidiary Chia Tai Tianqing Enters Exclusive Strategic Partnership with GSK to Accelerate China Launch of Hepatitis B Innovative Drug Bepirovirsen

NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) released a voluntary announcement on May 11, 2026. The Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has entered into an exclusive strategic cooperation with GlaxoSmithKline (GSK).
Under the terms of the agreement, Chia Tai Tianqing will be responsible for import, distribution, hospital access, as well as promotional and non-promotional activities of bepirovirsen in Chinese Mainland. All sales revenue generated from the product will be recognized as revenue of Chia Tai Tianqing.
GSK will remain the Marketing Authorization Holder (MAH) and be responsible for regulatory registration, quality control, pharmacovigilance, global medical strategies and other related work. Chia Tai Tianqing will purchase bepirovirsen from GSK under agreed supply terms for an initial cooperation period of 5.5 years, after which both parties may extend the term upon mutual agreement.
Bepirovirsen is a first-in-class antisense oligonucleotide (ASO) with a triple mechanism of action for the treatment of chronic hepatitis B (CHB) in adults. The product was included in the Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the NMPA in August 2021, and granted Priority Review in April 2026.
Phase 3 clinical studies B-Well 1 and B-Well 2 demonstrated statistically and clinically significant functional cure rates.
Hepatitis B is a viral liver infection. An estimated 75 million people in China are living with hepatitis B virus infection, with more than 450,000 related deaths annually. Approximately 84.4% of liver cancer cases are associated with chronic hepatitis B infection.
Chia Tai Tianqing is a market leader in the hepatitis B sector in China, owning one of the most comprehensive liver disease product portfolios domestically and establishing an extensive commercial network covering more than 5,000 medical institutions at all levels.
The Company stated that this partnership marks another high recognition from a world-leading multinational pharmaceutical company, following the strategic cooperation reached with Boehringer Ingelheim in April 2024.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.